Eli Lilly & Co
LLY- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000059478
In the last 90 days, Eli Lilly & Co insiders filed 0 open-market purchases and 2 sales; 4,664 institutions reported holding it in 13F filings for Q2 2026, worth $942.9B in total; 4 superinvestors hold it, including ARK Invest and Soros Fund Management.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 30, 2026, 1:13 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 4, 2026 | Jan 14, 2025 | Feb 6, 2024 | Feb 2, 2023 | Feb 3, 2022 |
| Revenue | $65.2B | $45.0B | $34.1B | $28.5B | $28.3B |
| Cost of revenue | $11.1B | $8.42B | $7.08B | $6.63B | $7.31B |
| Research and development | $13.3B | $11.0B | $9.31B | $7.19B | $7.03B |
| Selling, general and administrative | $11.1B | $8.59B | $7.40B | $6.44B | $6.43B |
| Interest expense | – | – | $485.9M | $331.6M | $339.8M |
| Income tax | $5.09B | $2.09B | $1.31B | $561.6M | $573.8M |
| Net income | $20.6B | $10.6B | $5.24B | $6.24B | $5.58B |
| EPS, basic | $23.00 | $11.76 | $5.82 | $6.93 | $6.15 |
| EPS, diluted | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 |
| Weighted shares, basic | 897.3M | 900.6M | 900.2M | 901.7M | 907.0M |
| Weighted shares, diluted | 899.3M | 904.1M | 903.3M | 904.6M | 911.7M |
| Margins and growth | |||||
| Net margin | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% |
| Revenue growth, year over year | +44.7% | +32.0% | +19.6% | +0.8% | +15.4% |
| Net income growth, year over year | +94.9% | +102.1% | −16.1% | +11.9% | −9.9% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 4, 2026 | Jan 14, 2025 | Feb 6, 2024 | Feb 2, 2023 | Feb 3, 2022 |
| Cash and equivalents | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B |
| Short-term investments | – | $154.8M | $109.1M | $144.8M | $90.1M |
| Accounts receivable | $17.8B | $11.0B | $9.09B | $6.90B | $6.67B |
| Inventory | $13.7B | $7.59B | $5.77B | $4.31B | $3.89B |
| Total current assets | $55.6B | $32.7B | $25.7B | $18.0B | $18.5B |
| Property, plant and equipment | $24.7B | $17.1B | $12.9B | $10.1B | $8.99B |
| Goodwill | $5.90B | $5.77B | $4.94B | $4.07B | $3.89B |
| Intangible assets | $6.52B | $6.17B | $6.91B | $7.21B | $7.69B |
| Total assets | $112.5B | $78.7B | $64.0B | $49.5B | $48.8B |
| Accounts payable | $5.38B | $3.23B | $2.60B | $1.93B | $1.67B |
| Short-term debt | $1.64B | $5.12B | $6.90B | $1.50B | $1.54B |
| Total current liabilities | $35.2B | $28.4B | $27.3B | $17.1B | $15.1B |
| Long-term debt | $40.9B | $28.5B | $18.3B | $14.7B | $15.3B |
| Shareholders' equity | $26.5B | $14.3B | $10.9B | $10.8B | $9.15B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 4, 2026 | Jan 14, 2025 | Feb 6, 2024 | Feb 2, 2023 | Feb 3, 2022 |
| Operating cash flow | $16.8B | $8.82B | $4.24B | $7.08B | $7.26B |
| Depreciation and amortization | $2.00B | $1.77B | $1.53B | $1.52B | $1.55B |
| Stock-based compensation | $626.0M | $645.6M | $628.5M | $371.1M | $342.8M |
| Dividends paid | $5.38B | $4.68B | $4.07B | $3.54B | $3.09B |
| Share buybacks | $4.11B | $2.50B | $750.0M | $1.50B | $1.25B |
| Investing cash flow | -$11.0B | -$9.30B | -$7.15B | -$3.26B | -$2.76B |
| Financing cash flow | -$2.21B | $1.23B | $3.50B | -$5.41B | -$4.13B |
| Net change in cash | $4.00B | $449.8M | $751.6M | -$1.75B | $161.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.0% | 1.4% | 1.8% | 1.3% | 1.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 26, 2026 | 940.7M | −0.5% | SEC |
| Aug 3, 2026 | 941.4M | −0.5% | SEC |
| Apr 27, 2026 | 941.7M | −0.6% | SEC |
| Feb 9, 2026 | 943.4M | −0.5% | SEC |
| Oct 27, 2025 | 945.4M | −0.4% | SEC |
| Aug 4, 2025 | 946.5M | −0.4% | SEC |
| Apr 28, 2025 | 947.7M | −0.3% | SEC |
| Feb 14, 2025 | 948.2M | −0.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.